Introduction {#S0001}
============

Anemia is the most common hematological disorder. We define anemia to be when hemoglobin (Hb) and hematocrit (HCT) levels are below the normal reference range according to WHO criteria. In males, anemia is diagnosed when Hb is \<13 g/dL and HCT is \<39%, whereas in females, anemia is when Hb is \<12 g/dL and HCT is \<36%.[@CIT0001] Twenty percent of all hospital admissions among the elderly are due to anemia.[@CIT0002]

Anemia may be caused by nutrient deficiencies (iron, folic acid and vitamin B12), sickle cell disease, AIDS, malaria, hookworm infection, and other infections.[@CIT0003] Anemia is one of the most common blood abnormalities in people with HIV. The incidence of anemia ranges from 10% in people who have no HIV symptoms to 92% in individuals who have advanced AIDS.[@CIT0004]

The hematological manifestations of HIV infection are complications of the disease which may be clinically important in patients. An obvious cause of anemia in patients with HIV infection is blood loss. Other than blood loss, HIV-associated anemia may cause decreased red blood cell/RBC production, increased RBC destruction and ineffective RBC production.[@CIT0005],[@CIT0006],[@CIT0007]

Anemia which is also one of the major challenges among HIV patients can lead to impaired physical functioning, psychological distress, poor quality of life, accelerated disease progression, and shorter life expectancy.[@CIT0005] Although anemia can occur at any stage of HIV infection, its severity is correlated with progression of the HIV disease stage. A study conducted in the very early years of HIV discovery shows the overall prevalence of anemia to be about 28% among people with HIV infection in the pre-AIDS stage of the disease, whereas it could reach as high as 71% in the advanced or AIDS stage of the HIV disease.[@CIT0009]

According to reports, the prevalence of anemia among adult HIV patients taking ART ranges between 23% and 50% globally[@CIT0004],[@CIT0006],[@CIT0010] and between 24% and 58% in Africa.[@CIT0011],[@CIT0012] Generally, the prevalence of anemia tends to be higher in ART-naïve patients compared to ART users.[@CIT0018],[@CIT0019] In Ethiopia, the prevalence of anemia among ART-naïve adult HIV patients was reported to reach up to 35%.[@CIT0013] A study done 3 years ago in the southwest part of Ethiopia has shown the prevalence of anemia to be 29.9% and 16.2% among ART-naïve and ART-experienced HIV patients, respectively.[@CIT0014]

There are different reports that show a large number of both HIV/AIDS and anemia in Ethiopia. However, the burden of anemia among people living with HIV/AIDS and receiving ART is not fully understood in Gedeo zone health institutions. Hence, this study is designed to assess the prevalence of anemia and associated factors among adult HIV/AIDS clients receiving ART at Gedeo zone health institutions, SNNPR, Ethiopia.

Materials And Methods {#S0002}
=====================

Study Setting And Design {#S0002-S2001}
------------------------

Multicenter institution--based cross-sectional study was conducted in selected governmental health institutions in Gedeo zone, SNNP regional state of Ethiopia from March to April, 2018 . The zone has 8 werdas and 2 city administrations. There are 38 health centers in the zone and 4 hospitals, including Dilla University Referral Hospital, but only the 7 health centers and 4 hospitals have ART services.

### Study Population {#S0002-S2001-S3001}

The study population for this study was all HIV-positive adults aged 15 years and above who ever started first-line ART at the selected health institutions between February 2010 and 2017 in Gedeo zone, SNNP, Ethiopia. All HIV-positive adults (age ≥15 years) on ART for at least 6 months were included, because adequate exposure to treatment is considered if the patient takes the drug for at least 6 months. It is also related to the time in which the treatment started to suppress the virus and the immunity becomes reconstituted. Patients who have less than two follow-up CD4 counts, transferred in and who had incomplete information about the outcome variable were excluded. The sample size was 422; it was calculated using sample size calculation formula taking confidence level=95%, power=80%, prevalence of anemia among HIV patients=52.3%[@CIT0015] and by adding 10% non-response rate.

Data Collection Instruments And Procedure {#S0002-S2002}
-----------------------------------------

Socio-demographic details such as age, gender, residence, employment status, level of education and marital status were collected using interviewer-administered questionnaire. A standardized data extraction checklist was prepared by the investigators in English and was collected from patient chart and log book. The 2011 World Health Organization (WHO) report on the Hb concentration level to diagnose anemia was used in the hospital.[@CIT0016] Accordingly, anemia for males is defined as the Hb concentration \<13 g/dL (11.0--12.9 g/dL=mild; 8.0--10.9 g/dL moderate, and \<8.0 g/dL=severe), whereas anemia for females is defined as Hb \<12.0 (11.0--11.9 g/dL=mild, 8.0--10.9 g/dL=moderate, and \<8.0 g/dL=severe). Five BSC nurses who had experience in working at the ART clinic participated in the data collection process after one-day training and were supervised by 4 supervisors. The data clerks and card room workers supported them by identifying the cards of patients.

Data Processing And Analysis {#S0002-S2003}
----------------------------

Data were entered into EPI info version 7 and transferred to STATA version 12.0 for analysis. Descriptive and summary statistics were carried out. The data analysis ranged from the basic description of outcomes to the identification of statistically significant associations. Accordingly, simple frequencies, measure of central tendencies and measure of dispersions were computed. Bivariate analysis and multiple logistic models were used to show the relationship between anemia and various associated factors. Finally, all explanatory variables that were significantly associated with the outcome variable in the bivariate analyses (P \< 0.25) were entered into the multivariable logistic regression model to identify independent predictors of anemia. The adjusted odds ratio (AOR) with 95% confidence interval (CI) was calculated to show the strength of association. In multivariable analysis, variables with a P-value of \<0.05 were considered as statistically significant.

Results {#S0003}
=======

Socio-Demographic And Clinical Characteristics {#S0003-S2001}
----------------------------------------------

In this study, a total of 422 patients were included. The majority of the patients (56.7%) were females and 42.3% of the study participants were in the age group of 40--49 years with a mean age of 33.85 (SD = ±9. 12) years. Most of the study participants (68.8%)functional status was working ([Table 1](#T0001){ref-type="table"}).Table 1Socio-Demographic And Clinical Characteristics Of Adult HIV Patients On First-line ART In Gedeo Zone 2018VariableCategoryFrequencyPercentAge\<30 years13131.530--39 years17642.340--49 years8019.2\>50 years297Educational statusNo formal education11226.5Primary15135.8Secondary and above13231.34410.48Occurrence OIYes20248.6No19847.6OccupationUnemployed28968.5Employed368.5Merchant368.5CD4(cells/mm^3^)\<20018143.5200--49915537.3\>5008019.2Functional statusWorking34066.80Ambulatory14528.49Bedridden234.52WHO stageStage 112224.06Stage 29117.95Stage 326552.27Stage 4285.52

Prevalence Of Anemia {#S0003-S2002}
--------------------

The prevalence of anemia was 34.8% (95% CI 30.1--39.8) while about 7.4%, 14.3%, and 13.1% of the patients had severe, moderate, and mild prevalence of anemia, respectively. The mean hemoglobin was 14.6 (SD=±10. 8), (95% CI 13.6--15.8). Among those anemic patients, 55% were females, the majority (80%) used 1E drug regimen, 40% were in the age group of 40--49 years, the majority (70%) of them had poor adherence to ART, 48% had opportunistic infections and 47.6% used isoniazid prophylaxis.

Factors Associated With Anemia {#S0003-S2003}
------------------------------

In the bivariate logistic regression type of regimen, occupation, educational status, INH, opportunistic infection, functional status, BMI (malnutrition) and adherence were statistically significant factors of anemia in adult HIV-infected patients on first-line ART. In the multivariable logistic regression, Using INH and bedridden functional status were statistically determinants of anemia ([Table 2](#T0002){ref-type="table"}).Table 2Bivariate And Multivariable Logistic Regression Analysis Of Anemia And Associated Factors Among Adult People Living With HIV/AID Receiving Anti-Retroviral Therapy At Gedeo Zone, SNNPR, Ethiopia, 2018VariableCrude OR (95% CI)Adjusted OR (95% CI)Not AnemicAnemicINH given No936911 Yes175701.85(1. 25, 2.5)1.8(1.1, 2.9)\*Opportunistic infection No1356811 Yes132711.99(0.7, 5.5)1.34(0.2, 10.4)Adherence Good1941030.51(0.20, 1.31)0.56(0.2, 1.8) Poor703311Functional status Working2068511 Ambulatory58571.14(0.4,3.7)2.7(0.63, 11) Bedridden1152.75(0.83, 9)5.48(1.25, 23.8)\*BMI(malnutrition) Not malnourished22110611 Malnourished54412.2(0.96, 5.1)1.65(0.95, 2.85)Regimen\* 1b,1a &1c1350.24(0.03, 2.13)2.4(0.2,3.45) 1d960.95(0.3,3.1)0.9(0.3,2.7) 1e2251170.76(0.4,0.96)3.2(0.30.34.4) 1f271911[^1][^2]

Discussion {#S0004}
==========

The prevalence of anemia in this study was 34.8% (95% CI 30.1--39.8). This is within the range of different studies conducted on the prevalence of anemia among adult HIV patients taking ART (23% and 50% globally and 24% and 58% in Africa).[@CIT0011],[@CIT0012] In general, the prevalence of anemia tends to be higher in ART-naïve patients compared to ART users. In another study in Ethiopia, the prevalence of anemia among ART-naïve adult HIV patients was reported to reach up to 35%.[@CIT0017] The incidence of anemia ranges from 10% in people who have no HIV symptoms to 92% in individuals who have advanced AIDS.[@CIT0004] A study conducted in the very early years of HIV discovery had shown the overall prevalence of anemia to be about 28% among people with HIV infection in the pre-AIDS stage of the disease, whereas it could reach as high as 71% in the advanced or AIDS stage of the HIV disease.[@CIT0009] The prevalence of anemia in this study was lower than the findings of studies conducted in China,[@CIT0015] which was 39.2% and 52.3% in Arbaminch,[@CIT0015] but it is higher than the studies conducted in Debretabor Hospital,[@CIT0017] which was 23% and 16.2% in southwest Ethiopia.[@CIT0013]

In this study, those patients who had bedridden functional status were 5.5 times more anemic than those who are working. INH users were 1.8 times more anemic. This finding is in line with a study conducted among adult HIV patients in Ethiopia: a hospital-based cross-sectional study.[@CIT0017] This might be due to that INH causes vitB6 deficiency which leads to anemia due to malabsorption of nutrients.

Conclusion {#S0005}
==========

In this study, the prevalence of anemia was 34.8%. Functional status and INH were determinant factors of anemia. Based on the results, we recommend hospitals establish and rapidly expand awareness and counseling program to facilitate and motivate HIV-infected patients to improve their adherence and nutritional intake. Moreover, health care providers managing HIV patients should treat INH side effects and should prescribe iron and vitB6 supplementation to those malnourished and anemic patients.
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[^1]: **Notes:** \*ART Regimen: 1a=d4T-3TC-NVP, 1b= d4T-3TC-EFV, 1c=AZT-3TC-NVP, 1d=AZT-3TC-EFV, 1e=TDF-3TC-EFV, 1f=TDF+3TC+NVP.

[^2]: **Abbreviations:** Drug names: d4T, Stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; AZT, Zidovudine or azidothymidine; TDF, tenofovir disoproxil fumarate.
